A
Annoroad
A leading developer and marketer on genomic innovation technologies for research and clinical market
About Annoroad
Annoroad is a biotechnology company headquartered in Beijing, China, that was founded in 2012 by Junbin Liang and Chongjian Chen. The company specializes in the application of next-generation sequencing (NGS) technology to provide a range of services to the research and clinical markets.
Read full description
Annoroad's business model is centered on providing integrated solutions for genomics research and diagnostics. This includes a variety of sequencing services, such as single-cell sequencing, epigenetic sequencing, and transcriptome sequencing. In the clinical diagnostics space, the company has developed and offers a number of products, including non-invasive prenatal testing (NIPT), genetic testing for hereditary tumors, and testing for rare diseases. Annoroad serves a diverse client base that includes hospitals, research institutions, and pharmaceutical companies.
The company has a significant research and development focus, with a team of scientists and bioinformaticians dedicated to developing new applications for genomic technologies. Annoroad has also established a number of partnerships with academic institutions and other companies in the life sciences industry to advance its research and development efforts.
At a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Dongcheng District, China
- Employees
- 28
- Open positions
- None listed
- Dealroom signal
- 74.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Alternative Medicine, Testing, Biotechnology, Oncology, DNA, Genetics and genomics, Sequencing, Non-Invasive medical devices and treatments
- Technology
- Big Data, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Mar 2024
- Capital deployed
- $2.8M
- Preferred round
- EARLY VC
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | Mar 2025 | $0 | — | Undisclosed | ↗ |
| SERIES C✓Equity / VC | Nov 2017 | $100M | $400M | SAIF Partners · SB China Capital · Ping An Ventures · ShenZhen GTJA Investment Group | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Annoroad is 160 monthly website visits, down 66% over the last three months. Annoroad's team grew 3.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
SAIF Partners
SB China Capital
Ping An Ventures- SGShenZhen GTJA Investment Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Annoroad on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Annoroad’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.